About Us

The government of Malaysia has identified biotechnology as another potential area to be the engine of growth. In 2005, the National Biotechnology Policy (NBP) was then established with the main aim to turn the biotechnology sector into one of the key economic drivers for the nation, contributing 5% of the nation’s GDP by 2020. NBP was designed to provide a comprehensive roadmap that would foster a conducive ecosystem for accelerated growth in the biotechnology industry to be implemented with three 5-year Phases:

·       Phase I (2005 – 2010): Capacity Building
·       Phase II (2011 – 2015): Science to Business
·       Phase III (2016 – 2020: Global Presence
The National Biotechnology Division (BIOTEK) under the Ministry of Science, Technology and Innovation (MOSTI) has been given the responsibility to lead the national agenda through R&D, technology development and promotion of biotechnology programs. 

In 2002, three interim laboratories - Genomic & Molecular Biology; Agro-Biotechnology; and Pharmaceuticals & Nutraceuticals were established to provide research infrastructure for the 8th Malaysia Plan for National Biotechnology Agenda  led by the Biotechnology Cooperative Centres (BCCs).

In 2005, these laboratories were inaugurated as National Biotechnology Institutes to lead, coordinate and implement the national biotechnology agenda through activities research, development, innovation and commercialization (RDIC). The three National Biotechnology Institutes are:

·       Malaysia Agro-Biotechnology Institute (ABI)
·       Malaysia Institute of Pharmaceuticals and Nutraceuticals (IPHARM)
·       Malaysia Genome Institute (MGI) 

In 2011, the institutes were restructured and placed under an autonomous organization called the National Institutes of Biotechnology Malaysia (NIBM). While the three institutes focus on high quality and market driven R&D and innovations, NIBM’s key role is to support and spearhead the commercialization of the R&D activities at the institutes based on industry requirements. NIBM was eventually registered on 27 January 2012 as a Company Limited by Guarantee (CLG) not for profit under the purview of MOSTI and began operations on 1st March 2012.

The pursuit of commercialization activities at NIBM is driven by the following key components:

1.    Market-driven & lab to market R&D
2.    Industry partnership
3.    Talent & expertise training
4.    Repository natural bio-resources
5.    Shared core facilities
6.    International collaboration